Shares of Pacira Pharmaceuticals Inc. (NASDAQ:PCRX) rose 3% on Monday . The company traded as high as $38.62 and last traded at $37.35, with a volume of 930,110 shares changing hands. The stock had previously closed at $36.25.

PCRX has been the subject of a number of recent analyst reports. Canaccord Genuity reiterated a “buy” rating on shares of Pacira Pharmaceuticals in a research report on Wednesday, April 20th. BMO Capital Markets initiated coverage on Pacira Pharmaceuticals in a research report on Tuesday, June 28th. They set an “underperform” rating and a $36.00 target price for the company. Mizuho reiterated a “buy” rating and set a $64.00 target price on shares of Pacira Pharmaceuticals in a research report on Wednesday, July 20th. Wedbush reiterated an “outperform” rating and set a $105.00 target price on shares of Pacira Pharmaceuticals in a research report on Wednesday, June 22nd. Finally, Zacks Investment Research upgraded Pacira Pharmaceuticals from a “sell” rating to a “hold” rating in a research report on Tuesday, April 26th. Two equities research analysts have rated the stock with a sell rating, three have issued a hold rating and seven have assigned a buy rating to the company. Pacira Pharmaceuticals has a consensus rating of “Hold” and a consensus target price of $73.82.

The stock’s market capitalization is $1.40 billion. The stock has a 50-day moving average price of $37.62 and a 200 day moving average price of $50.48.

Pacira Pharmaceuticals (NASDAQ:PCRX) last issued its quarterly earnings results on Monday, May 2nd. The company reported $0.15 EPS for the quarter, topping analysts’ consensus estimates of $0.07 by $0.08. The company earned $65.50 million during the quarter, compared to the consensus estimate of $67.11 million. During the same period in the prior year, the firm earned $0.27 earnings per share. The business’s revenue for the quarter was up 12.3% compared to the same quarter last year. Equities analysts forecast that Pacira Pharmaceuticals Inc. will post $0.29 earnings per share for the current year.

In related news, Director Mark A. Kronenfeld sold 900 shares of the company’s stock in a transaction that occurred on Monday, June 6th. The stock was sold at an average price of $46.95, for a total value of $42,255.00. Following the transaction, the director now directly owns 2,950 shares of the company’s stock, valued at approximately $138,502.50. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, CAO Kristen Marie Williams sold 600 shares of the company’s stock in a transaction that occurred on Monday, June 6th. The shares were sold at an average price of $47.20, for a total value of $28,320.00. Following the completion of the transaction, the chief accounting officer now directly owns 6,900 shares in the company, valued at $325,680. The disclosure for this sale can be found here.

A number of institutional investors have added to or reduced their stakes in PCRX. KBC Group NV boosted its position in Pacira Pharmaceuticals by 2,685.7% in the fourth quarter. KBC Group NV now owns 28,024 shares of the company’s stock valued at $2,152,000 after buying an additional 27,018 shares during the period. Stephens Investment Management Group LLC boosted its position in Pacira Pharmaceuticals by 10.0% in the fourth quarter. Stephens Investment Management Group LLC now owns 540,687 shares of the company’s stock valued at $41,519,000 after buying an additional 49,018 shares during the period. Stephens Inc. AR boosted its position in Pacira Pharmaceuticals by 3.9% in the fourth quarter. Stephens Inc. AR now owns 21,557 shares of the company’s stock valued at $1,655,000 after buying an additional 806 shares during the period. Morgan Stanley boosted its position in Pacira Pharmaceuticals by 28.7% in the fourth quarter. Morgan Stanley now owns 120,614 shares of the company’s stock valued at $9,261,000 after buying an additional 26,865 shares during the period. Finally, Mutual of America Capital Management LLC boosted its position in Pacira Pharmaceuticals by 0.6% in the fourth quarter. Mutual of America Capital Management LLC now owns 24,198 shares of the company’s stock valued at $1,858,000 after buying an additional 142 shares during the period.

Pacira Pharmaceuticals, Inc is a specialty pharmaceutical company. The Company is focused on the development, commercialization and manufacture of pharmaceutical products, based on its DepoFoam drug delivery technology, for use in hospitals and ambulatory surgery centers. Its primary focus lies in the development of non-opioid products for postsurgical pain control.

Get Analysts' Upgrades and Downgrades Daily - Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.